10x Genomics, Inc. TXG
65.15 USD +3.52 (+5.71%)
Nov 3, 2026, 3:49 PM EST
62.51 Day range 66.19
12.80 52-week range 102.81
- YTD
- +299.45%
- 1 year
- +375.55%
Analyst view
Consensus: buy
Buy
Price target (mean) 77.50 +19.0% upside
Now 65.15
- Target (low)
- 50.00
- Target (mean)
- 77.50
- Target (high)
- 110.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy1
- Buy5
- Hold12
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 19
- 2 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.02 | -0.04 – 0.00 | -0.0228 | +12.3% | 147.85M | -0.8% | 2 |
| Next quarter | -0.005 | -0.06 – 0.05 | 0.0705 | -107.1% | 171.51M | +3.3% | 2 |
| Current year | 0.03667 | -0.10 – 0.18 | 0.1231 | -70.2% | 620.58M | -3.5% | 3 |
| Next year | 0.07667 | 0.01 – 0.17 | 0.03667 | +109.1% | 683.34M | +10.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Maintained | Hold | Hold |
| Oct 13, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 29, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Sep 28, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Sep 28, 2026 | Argus Research | Initiated | — | Buy |
| Sep 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Sep 1, 2026 | RBC Capital | Initiated | — | Sector Perform |
| Aug 12, 2026 | Stephens & Co. | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 10, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 17, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Jul 14, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 9, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 8, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 1, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 12, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 12, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Apr 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 20, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 7, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Mar 31, 2026 | William Blair | Upgrade | Market Perform | Outperform |
| Mar 2, 2026 | Stifel | Maintained | Buy | Buy |
| Feb 20, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 13, 2026 | Stifel | Maintained | Buy | Buy |
